false 0001034842 0001034842 2024-09-16 2024-09-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): September 16, 2024

 

RIGEL PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

(State or other jurisdiction of incorporation)

 

0-29889   94-3248524
(Commission File No.)   (IRS Employer Identification No.)
     
611 Gateway Boulevard, Suite 900    
South San Francisco, CA    94080
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (650) 624-1100

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Title of Each Class   Trading
Symbol(s)		   Name of Each Exchange on Which
Registered
Common Stock, par value $0.001 per share   RIGL   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 5.02.Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On September 16, 2024, Dr. Brian Kotzin notified Rigel Pharmaceuticals, Inc. (“Rigel”) of his decision to resign as a member of the Board of Directors of Rigel (the “Board”) and from the committees on which he serves, effective September 16, 2024. At the time of Dr. Kotzin’s resignation, he was an independent director and member of the Corporate Governance, Healthcare Compliance Oversight, and Nominating Committee of the Board, and chair of the Scientific and Clinical Trial Advisory Committee of the Board. Dr. Kotzin’s decision to resign was not a result of any disagreement with Rigel on any matter relating to the Rigel’s operations, policies or practices.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: September 19, 2024 RIGEL PHARMACEUTICALS, INC.
   
  By: /s/ Raymond J. Furey
    Raymond J. Furey
    Executive Vice President, General Counsel, Chief Compliance Officer, and Corporate Secretary

 

 

 

v3.24.3
Cover
Sep. 16, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Sep. 16, 2024
Entity File Number 0-29889
Entity Registrant Name RIGEL PHARMACEUTICALS, INC.
Entity Central Index Key 0001034842
Entity Tax Identification Number 94-3248524
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 611 Gateway Boulevard,
Entity Address, Address Line Two Suite 900
Entity Address, City or Town South San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94080
City Area Code 650
Local Phone Number 624-1100
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol RIGL
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Rigel Pharmaceuticals (NASDAQ:RIGL)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025 Rigel Pharmaceuticals 차트를 더 보려면 여기를 클릭.
Rigel Pharmaceuticals (NASDAQ:RIGL)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025 Rigel Pharmaceuticals 차트를 더 보려면 여기를 클릭.